Loading company…
Nanophoria develops an inhalable nanoparticle platform for delivering biologic medicines.
Nanophoria is a preclinical biotechnology company developing non-viral drug delivery using inorganic nanoparticles. Its lead candidate, NP-MP1, is an inhalable formulation being developed for heart failure with reduced ejection fraction. Based in Milan, Italy, the company raised EUR 15 million in Series A funding from the European Innovation Council in January 2026, as part of a larger EUR 83.5 million Series A.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in